Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
jeudi, octobre 22
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Immunic Inc
IMUX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$7.48
0.07
0.94%
Dern. MÀJ: Oct 21, 5:50 PM
$7.56
0.15
2.03%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Immunic Financials
Immunic (IMUX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 60 percent increase over losses of $(2.00) per share from the same
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
Immunic Q1 EPS $(1.08) Misses $(0.91) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.68 percent. This is a 332 percent decrease over losses of $(0.25) per share from the same
Benzinga Newsdesk
PRO
Immunic Q4 EPS $(0.07) Beats $(0.09) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 18.6 percent. This is a 72 percent increase over losses of $(0.25) per share from the same
Benzinga Newsdesk
PRO
Immunic Q3 EPS $(0.13) Beats $(0.18) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 26.14 percent. This is a 45.83 percent increase over losses of $(0.24) per share from the same
Benzinga Newsdesk
PRO
Immunic Q2 EPS $(0.20) Misses $(0.17) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 4.76 percent increase over losses of $(0.21) per share from the same
Benzinga Newsdesk
